Combination therapy of JNJ-67856633, a novel, first-in-class MALT1 protease inhibitor, and JNJ-64264681, a novel BTK inhibitor, for the treatment of B-cell lymphomas.

被引：0
|
作者：
Philippar, Ulrike [1 ]
Fontan, Lorena [1 ]
Cornelissen, Ivo [1 ]
Rui, Haopeng [2 ]
Balasubramanian, Sriram [3 ]
Gaudiano, Marcello [1 ]
Bekkers, Mariette [1 ]
Van Nuffel, Luc [1 ]
Lu, Tianbao [4 ]
Lu, Tianbao [4 ]
Wiener, John [5 ]
Tichenor, Mark [3 ]
Greway, Tony [6 ]
Packman, Kathryn [7 ]
Verbist, Bie [1 ]
Elsayed, Yusri [4 ]
Attar, Ricardo [4 ]
Bussolari, Jacqueline [6 ]
Gerecitano, John [6 ]
机构：
[1] Janssen Res & Dev, Beerse, Belgium
[2] Janssen Res & Dev, Shanghai, Peoples R China
[3] Janssen Res & Dev, La Jolla, CA USA
[4] Janssen Res & Dev, Spring House, PA USA
[5] Lundbeck Jolla Res Ctr Inc, La Jolla, CA USA
[6] Janssen Res & Dev, Raritan, NJ USA
[7] Janssen Res & Dev, Boston, MA USA
来源：
CANCER RESEARCH | 2021年 / 81卷 / 13期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1267
引用
收藏
页数：2
相关论文
共 10 条
  • [1] Discovery of JNJ-67856633: A novel, first-in-class MALT1 protease inhibitor for the treatment of B cell lymphomas
    Philippar, Ulrike
    Lu, Tianbao
    Vloemans, Nele
    Bekkers, Mariette
    Van Nuffel, Luc
    Gaudiano, Marcello
    Wnuk-Lipinska, Katarzyna
    Van der Leede, Bas-jan
    Amssoms, Katie
    Kimpe, Kristof
    Medaer, Bart
    Greway, Tony
    Abraham, Yann
    Cummings, Max
    Trella, Emanuele
    Vanhoof, Greet
    Sun, Weimei
    Thuring, Jan Willem
    Connolly, Peter
    Linders, Jan
    Rui, Haopeng
    Balasubramanian, Sriram
    Johnson, Amy
    Gerecitano, John
    Goldberg, Jenna
    Edwards, James P.
    Elsayed, Yusri
    Smit, Jennifer
    Bussolari, Jaqueline
    Attar, Ricardo
    CANCER RESEARCH, 2020, 80 (16)
  • [2] Discovery of AUR-112, a novel MALT1 protease inhibitor for the treatment of B cell lymphomas
    Balasubramanian, Wesley Roy
    Raju, Sammeta Srinivasa
    Vasantha, K. Y.
    Reddy, Archana Bhumi
    Maben, Janith Mary
    Patil, Sandeep Sadashiv
    Raghavendra, N. R.
    Aithal, Kiran B.
    Charamanna, K. B.
    Chikkanna, Dinesh
    Nellore, Kavitha
    Samiulla, D. S.
    Daginakatte, Girish
    Chelur, Shekar
    Ramachandra, Murali
    Samajdar, Susanta
    MOLECULAR CANCER THERAPEUTICS, 2023, 22 (12)
  • [3] ONO-7018, a First-in-Class MALT1 Inhibitor, Provides Novel Therapeutic Strategies for B Cell Malignancies: Overcoming BTK Inhibitor Acquired Resistance and Enhancing the Antitumor Effect of BTK Inhibitors
    Fujikawa, Ryu
    Komichi, Yuka
    Ono, Kazuya
    Yasuhiro, Tomoko
    Prados, Sergio
    Yoshida, Takao
    Kozaki, Ryohei
    BLOOD, 2023, 142
  • [4] A phase Ia/Ib study of a novel BTK inhibitor, DTRMWXHS-12 (DTRM 12), and combination products, with everolimus and pomalidomide, in pts with CLL or other B-cell lymphomas.
    Gill, Jennifer
    He, Wei
    Schuster, Stephen J.
    Brander, Danielle M.
    Chatburn, Elizabeth
    Kennard, Kaitlin
    Anderson, Barry Douglas
    Nasta, Sunita
    Landsburg, Daniel Jeffrey
    Porter, David L.
    Napier, Ellen
    Latorre, Tanya
    Svoboda, Jakub
    Addis, Victoria
    Mato, Anthony R.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [5] CG-806, a first-in-class FLT3/BTK inhibitor, and venetoclax synergize to inhibit cell proliferation and to induce apoptosis in aggressive B-cell lymphomas
    Rastgoo, Nasrin
    Thayer, Matthew
    Benbatoul, Khalid
    Howell, Stephen
    Rice, William
    Zhang, Hongying
    CANCER RESEARCH, 2020, 80 (16)
  • [6] Recurrent BCL10 mutations drive BTK inhibitor resistance in BN2-subtype diffuse large B-cell lymphomas by constitutively activating NF-kB and the MALT1 protease
    Coughlin, Caroline A.
    Kumar, Preet
    Roberts, Evan R.
    Lopez, Horacio Gonzalez
    Lekakis, Marianna
    Li, Lingxio
    Bilbao, Daniel
    Schatz, Jonathan H.
    CANCER RESEARCH, 2022, 82 (12)
  • [7] A first-in-class inhibitor of HSP110 to potentiate XPO1-targeted therapy in primary mediastinal B-cell lymphoma and classical Hodgkin lymphoma
    Durand, Manon
    Gibouin, Vincent Cabaud
    Duplomb, Laurence
    Salmi, Leila
    Caillot, Melody
    Sola, Brigitte
    Camus, Vincent
    Jardin, Fabrice
    Garrido, Carmen
    Jego, Gaetan
    JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH, 2024, 43 (01)
  • [8] A Phase Ia/Ib Study Exploring the Synthetic Lethality of the Orally Administered Novel BTK Inhibitor, Dtrmwxhs-12 (DTRM-12), in Combination with Everolimus and Pomalidomide in Patients with Relapsed/Refractory CLL, DLBCL or Other B-Cell Lymphomas
    Mato, Anthony R.
    Schuster, Stephen J.
    Foss, Francine M.
    Isufi, Iris
    Ding, Wei
    Brander, Danielle M.
    Sitlinger, Andrea
    Tun, Han W.
    Moustafa, Muhamad Alhaj
    Kennard, Kaitlin
    King, Cara M.
    Koehler, Amber
    Aitken, Casey
    He, Wei
    Kearney, Albert
    Gui, Min
    Anderson, Barry Douglas
    Rosenthal, Allison C.
    Roeker, Lindsey E.
    Huntington, Scott F.
    BLOOD, 2019, 134
  • [9] A Phase 1b-2 Study of KRT-232, a First-in-Class, Oral, Small Molecule Inhibitor of Murine Double Minute 2 (MDM2), in Combination with Acalabrutinib for the Treatment of Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) or R/R Diffuse Large B-Cell Lymphoma (DLBCL)
    Hillmen, Peter
    Qamoos, Hope
    Uyei, Anne
    Rothbaum, Wayne M.
    Jurczak, Wojciech
    Thieblemont, Catherine
    Byrd, John C.
    BLOOD, 2020, 136
  • [10] Phase 1b study of the novel first-in-class G protein-coupled estrogen receptor (GPER) agonist, LNS8801, in combination with pembrolizumab in patients with immune checkpoint inhibitor (ICI)-relapsed and refractory solid malignancies and dose escalation update
    Muller, Carolyn
    Chaney, Marya F.
    Cohen, Justine Vanessa
    Garyantes, Tina
    Lin, Jessica Jiyeong
    LoRusso, Patricia
    Mita, Alain C.
    Mita, Monica M.
    Natale, Christopher
    Orloff, Marlana M.
    Papadopoulos, Kyriakos P.
    Patel, Sapna Pradyuman
    Ahnert, Jordi Rodon
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
1